Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017:2017:3765253.
doi: 10.1155/2017/3765253. Epub 2017 Jun 27.

Effect of Topical Nepafenac on Central Foveal Thickness following Panretinal Photocoagulation in Diabetic Patients

Nahla B Abu Hussein  1 , Ahmed A Mohalhal  1 , Dalia A Ghalwash  1 , Ahmed A Abdel-Kader  1
Affiliations

Effect of Topical Nepafenac on Central Foveal Thickness following Panretinal Photocoagulation in Diabetic Patients

Nahla B Abu Hussein et al. J Ophthalmol. 2017.

Abstract

Purpose: To evaluate effectiveness of topical nepafenac in reducing macular edema following panretinal photocoagulation (PRP).

Design: Prospective randomized double-blinded controlled study.

Methods: Sixty eyes of 60 patients having proliferative or severe nonproliferative diabetic retinopathy had PRP. Patients were then divided into two groups: nepafenac group (30 eyes) receiving 1% topical nepafenac eye drops for 6 months and control group (30 eyes) receiving carboxymethylcellulose eye drops for 6 months. Best-corrected visual acuity (BCVA) and macular optical coherence tomography were followed up at 1, 2, 4, and 6 months after PRP.

Results: BCVA was significantly better in nepafenac group than in control group at all follow-ups (P < 0.01). At 6 months post-PRP, logMAR BCVA was 0.11 ± 0.04 (equivalent to 20/26 Snellen acuity) in the nepafenac group and 0.18 ± 0.08 (equivalent to 20/30 Snellen acuity) in the control group (P < 0.01). Central foveal thickness (CFT) increased in both groups from the first month after PRP. Increase in CFT was higher in control group than in nepafenac group throughout follow-up, but the difference became statistically significant only after 4 months. No significant ocular adverse events were reported with topical nepafenac.

Conclusion: Topical nepafenac can minimize macular edema and stabilize visual acuity following PRP for diabetic patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Best-corrected visual acuity (BCVA) at baseline and during follow-ups in nepafenac and control groups.
Figure 2
Figure 2
Central foveal thickness (CFT) at baseline and during follow-ups in nepafenac and control groups.
See this image and copyright information in PMC

References

    1. Flach A. J. Topical nonsteroidal antiinflammatory drugs in ophthalmology. International Ophthalmology Clinics. 2002;42(1):1–11. - PubMed
    1. Adamis A. P., Berman A. J. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Seminars in Immunopathology. 2008;30(2):65–84. - PubMed
    1. Johnson M. W. Etiology and treatment of macular edema. American Journal of Ophthalmology. 2009;147(1):11–12. - PubMed
    1. Zhou J., Wang S., Xia X. Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Current eye Research. 2012;37(5):416–420. - PubMed
    1. Schoenberger S. D., Kim S. J., Sheng J., Rezaei K. A., Lalezary M., Cherney E. Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. Investigative Ophthalmology & Visual Science. 2012;53(9):5906–5911. - PubMed

LinkOut - more resources